Sino-US tensions engendered by US president Donald Trump are driving both US and Chinese biotech firms, as well as biotech firms headquartered elsewhere, to list on the Hong Kong Stock Exchange (HKEX) instead of Nasdaq, formerly regarded as the premier initial public offering (IPO) destination of biotechs, according to speakers at a recent BIOHK conference in Hong Kong.

¬ Haymarket Media Limited. All rights reserved.